BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 15542195)

  • 1. Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria.
    Polley SD; Mwangi T; Kocken CH; Thomas AW; Dutta S; Lanar DE; Remarque E; Ross A; Williams TN; Mwambingu G; Lowe B; Conway DJ; Marsh K
    Vaccine; 2004 Dec; 23(5):718-28. PubMed ID: 15542195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1.
    Cortés A; Mellombo M; Masciantonio R; Murphy VJ; Reeder JC; Anders RF
    Infect Immun; 2005 Jan; 73(1):422-30. PubMed ID: 15618180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya.
    Osier FH; Weedall GD; Verra F; Murungi L; Tetteh KK; Bull P; Faber BW; Remarque E; Thomas A; Marsh K; Conway DJ
    Infect Immun; 2010 Nov; 78(11):4625-33. PubMed ID: 20732997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
    Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L
    Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variant-specific antibodies to merozoite surface protein 2 and clinical expression of Plasmodium falciparum malaria in rural Amazonians.
    Scopel KK; da Silva-Nunes M; Malafronte RS; Braga EM; Ferreira MU
    Am J Trop Med Hyg; 2007 Jun; 76(6):1084-91. PubMed ID: 17556615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A longitudinal study of seroreactivities to a major blood stage antigen (Pf155/RESA) of the malaria parasite Plasmodium falciparum in an endemic area of Thailand.
    Chirakalwasan N; Kamol-Ratanakul P; Lertmaharit S; Perlmann H; Perlmann P; Thaitong S
    Southeast Asian J Trop Med Public Health; 1994 Mar; 25(1):25-31. PubMed ID: 7529944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.
    Terheggen U; Drew DR; Hodder AN; Cross NJ; Mugyenyi CK; Barry AE; Anders RF; Dutta S; Osier FH; Elliott SR; Senn N; Stanisic DI; Marsh K; Siba PM; Mueller I; Richards JS; Beeson JG
    BMC Med; 2014 Oct; 12():183. PubMed ID: 25319190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apical membrane antigen 1: a malaria vaccine candidate in review.
    Remarque EJ; Faber BW; Kocken CH; Thomas AW
    Trends Parasitol; 2008 Feb; 24(2):74-84. PubMed ID: 18226584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies to polymorphic invasion-inhibitory and non-Inhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malaria.
    Mugyenyi CK; Elliott SR; McCallum FJ; Anders RF; Marsh K; Beeson JG
    PLoS One; 2013; 8(7):e68304. PubMed ID: 23861883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strain-specific humoral response to a polymorphic malaria vaccine.
    Flück C; Smith T; Beck HP; Irion A; Betuela I; Alpers MP; Anders R; Saul A; Genton B; Felger I
    Infect Immun; 2004 Nov; 72(11):6300-5. PubMed ID: 15501757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
    Malkin EM; Diemert DJ; McArthur JH; Perreault JR; Miles AP; Giersing BK; Mullen GE; Orcutt A; Muratova O; Awkal M; Zhou H; Wang J; Stowers A; Long CA; Mahanty S; Miller LH; Saul A; Durbin AP
    Infect Immun; 2005 Jun; 73(6):3677-85. PubMed ID: 15908397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.
    Bruder JT; Stefaniak ME; Patterson NB; Chen P; Konovalova S; Limbach K; Campo JJ; Ettyreddy D; Li S; Dubovsky F; Richie TL; King CR; Long CA; Doolan DL
    Vaccine; 2010 Apr; 28(18):3201-10. PubMed ID: 20188680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of antibodies to Plasmodium falciparum merozoite surface protein-4 with protection against clinical malaria.
    Perraut R; Varela ML; Joos C; Diouf B; Sokhna C; Mbengue B; Tall A; Loucoubar C; Touré A; Mercereau-Puijalon O
    Vaccine; 2017 Dec; 35(48 Pt B):6720-6726. PubMed ID: 29042203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection.
    John CC; Moormann AM; Pregibon DC; Sumba PO; McHugh MM; Narum DL; Lanar DE; Schluchter MD; Kazura JW
    Am J Trop Med Hyg; 2005 Jul; 73(1):222-8. PubMed ID: 16014863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya.
    Polley SD; Conway DJ; Cavanagh DR; McBride JS; Lowe BS; Williams TN; Mwangi TW; Marsh K
    Vaccine; 2006 May; 24(19):4233-46. PubMed ID: 16111789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmodium falciparum: a comparison of the activity of Pfs230-specific antibodies in an assay of transmission-blocking immunity and specific competition ELISAs.
    Roeffen W; Beckers PJ; Teelen K; Lensen T; Sauerwein RW; Meuwissen JH; Eling W
    Exp Parasitol; 1995 Feb; 80(1):15-26. PubMed ID: 7529717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum.
    Healer J; Murphy V; Hodder AN; Masciantonio R; Gemmill AW; Anders RF; Cowman AF; Batchelor A
    Mol Microbiol; 2004 Apr; 52(1):159-68. PubMed ID: 15049818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-reactivity studies of an anti-Plasmodium vivax apical membrane antigen 1 monoclonal antibody: binding and structural characterisation.
    Igonet S; Vulliez-Le Normand B; Faure G; Riottot MM; Kocken CH; Thomas AW; Bentley GA
    J Mol Biol; 2007 Mar; 366(5):1523-37. PubMed ID: 17229439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Protective antibody response to recombinant fragments of Plasmodium falciparum apical membrane antigen 1].
    Li X; Xue CF; Liu ZX; Wang XF; Ding J; Lei JC; Zhen RF
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2003; 21(2):80-3. PubMed ID: 12884614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.